Abstract:Abstract The objective of this study was to assess the ability of a commercially available blend of glycerides of C12 to inhibit porcine reproductive and respiratory syndrome virus (PRRSV) replication in porcine alveolar macrophages (PAM) and to investigate the immunomodulatory effect during PRRSV infection in vitro. PAM were collected by lung lavage from 4-wk-old piglets, free of PRRSV. PRRSV strain 13V091 was used in this study and a commercially available mixture of mono-, di- and tri-glycerides of lauric acid (GC12). The product concentrations tested were 0.022% (T1), 0.044% (T2) and 0.088% (T3). Three different infection assays were used: (1) Co-incubation; PRRSV was inoculated together with GC12 for 1 h, (2) Pre- and Post-infection; GC12 was added to PAM cells for 24 h before infection and after 1 h of incubation for another 24 h, and (3) Post-infection; GC12 was added only after PRRSV infection for 24 h. Titration of the progeny virus was performed on PAM from all three infection assays. Cytokine analysis was only performed for infection assay 2 and 3. Collected supernatants were subjected to multiplex ELISA to measure the level of TNF-α and IL-8. Two-tailed t test P value was used to determine statistically significant differences. P < 0.05 was considered to be statistically significant. Addition of GC12 in the Co-incubation assay did not reduce PRRSV infectivity at 24-h post infection (hpi; Table 1). In contrast, the Pre- and Post-infection assay showed significantly reduced PRRSV titer from 6 hpi onwards at concentration 0.044%. At concentration 0.088% a significant reduction was observed at 24 hpi. Addition of GC12 after PRRSV inoculation (post-infection) also showed significantly reduced PRRSV titer from 6 hpi onwards at concentration 0.044% and 0.088%. In the Pre- and Post-infection assay, all treatments with GC12 numerically increased the production of TNF-α at 24 hpi. A dose response effect was observed at 24 hpi with increasing concentrations of GC12 resulting in increasing levels of TNF-α. However, in the Post-infection assay only treatment with 0.088% GC12 numerically increased the production of TNF-α by 1.5-fold. Compared with the control (PAM+PRRSV), a significantly greater concentration of IL-8 was observed with 0.044% (P = 0.019) and 0.088% (P = 0.007) GC12 24 hpi in the Pre- and Post-infection assay (1,806 ± 376; 3,751 ± 636; 3,439 ± 420 pg/mL respectively). These two concentrations resulted in numeric increase of IL-8 24 hpi in the Post-infection assay and no effect was observed with 0.022% GC12 (Control 2,332 ± 998; T1 2,079 ± 964; T2 3,525 ± 344; T3 4,475 ± 295). From this study it can be concluded that GC12 exhibited antiviral activity against PRRSV strain 13V091 and influences the cytokine production of PAM during PRRSV infection, potentially neutralizing the suppression of the immune response by PRRSV.

In Vitro Evaluation of the Antiviral Activity of the Synthetic Epigallocatechin Gallate Analog-Epigallocatechin Gallate (EGCG) Palmitate Against Porcine Reproductive and Respiratory Syndrome Virus

(-)-Epigallocatechin-3-Gallate Inhibits The Life Cycle Of Pseudorabies Virus In Vitro And Protects Mice Against Fatal Infection

The Antiviral Activity of Caprylic Monoglyceride Against Porcine Reproductive and Respiratory Syndrome Virus in Vitro and in Vivo

Caffeic Acid Phenethyl Ester: an Effective Antiviral Agent Against Porcine Reproductive and Respiratory Syndrome Virus

Molecular Characterization of Three Porcine Reproductive and Respiratory Syndrome Virus Isolates and Their Susceptibility to Antiviral Drugs

In vitro screening for compounds derived from traditional chinese medicines with antiviral activities against porcine reproductive and respiratory syndrome virus.

Virucidal effects of eucalyptus essential oil on porcine reproductive and respiratory syndrome virus

Identification and Characterization of Small Molecule Inhibitors of Porcine Reproductive and Respiratory Syndrome Virus

EGCG Restricts PRRSV Proliferation by Disturbing Lipid Metabolism

The effect of matrine and glycyrrhizic acid on porcine reproductive and respiratory syndrome virus in Vitro and in vivo

Ursolic acid derivatives are potent inhibitors against porcine reproductive and respiratory syndrome virus

Cryptoporus Volvatus Extract Inhibits Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in Vitro and in Vivo

Small molecule screening identified cepharanthine as an inhibitor of porcine reproductive and respiratory syndrome virus infection in vitro by suppressing integrins/ILK/RACK1/PKCα/NF-κB signalling axis.

208 The antiviral and immunomodulating properties from glycerides of lauric acid in PRRSV-infected PAM cells

Effect of BIO-PLYTM, a Platelet-Rich Plasma Derived Biologic on PRRSV-2-infected macrophages

Efficacy of oleandrin and PBI-05204 against viruses of importance to commercial pig health management

Effect of Ethanolic Caesalpinia sappan Fraction on In Vitro Antiviral Activity against Porcine Reproductive and Respiratory Syndrome Virus

Natural Compound Sanggenon C Inhibits Porcine Reproductive and Respiratory Syndrome Virus Replication in Piglets

Assessing the antiviral activity of antimicrobial peptides Caerin1.1 against PRRSV in Vitro and in Vivo

Ginsenoside Rg1 Suppresses Type 2 PRRSV Infection via NF-κB Signaling Pathway In Vitro, and Provides Partial Protection against HP-PRRSV in Piglet

Therapeutic efficacy of tylvalosin combined with Poria cocos polysaccharides against porcine reproductive and respiratory syndrome